Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug

Stock Track

04/13

IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.

The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.

Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1197511698"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197511698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197511698?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197511698","market":"nz","top_or_hot":-1,"title":"Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug","media":"Stock Track","content":"<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-13 18:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.</p><p>The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.</p><p>Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"","article_id":"1197511698","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197511698","pubTimestamp":1776076722,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences"},"translate_title":"个股追踪|眼癌药物2/3期试验结果积极IDEAYA Biosciences盘前大涨31.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1},"content_text":"IDEAYA Biosciences (IDYA) stock surged 31.15% during pre-market trading on Monday following the announcement of positive clinical trial results for its experimental cancer treatment.The oncology company reported that its Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma, met its primary endpoint. The combination therapy showed a statistically significant improvement in median progression-free survival, extending it to 6.9 months compared to 3.1 months for the investigator's choice of therapy.Based on these results, IDEAYA Biosciences plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, aiming for accelerated approval of the treatment for this rare and aggressive form of eye cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}